myotwin develops human induced pluripotent stem cell derived organoid platforms that support animal-free drug discovery and development. The company focuses on generating functional human tissue models and measuring multiple functional parameters to assess drug efficacy and safety. Its technology provides quantitative data intended to improve prediction of human responses before clinical trials. myotwin works with pharmaceutical and biotech clients as a contract research partner, integrating organoid assays into preclinical pipelines. The offering centers on standardized assay design, data acquisition, and interpretation tailored to research and development decisions. By emphasizing human-relevant test systems, myotwin aims to reduce reliance on animal studies and streamline selection of promising therapeutic candidates.
